Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Metabolic |
| Evidence grade | A Human trial evidence |
| Regulatory status | Approved outside the US |
| Human amounts | Trial dosesDosing reference Study durations |
| Format | |
| Type | Single compound |
| Molecular formula | C194H304N48O61 |
| Molecular weight | 4,285 g/mol |
| CAS number | 2459531-73-6 |
| Sequence | Not listed |
| References | 13 |
| Summary | Ecnoglutide (XW003) is a long-acting, cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences that received its first approvals in China in 2026, for glycaemic control in type 2 diabetes and then for long-term weight management; it is not approved in the United States. |